Cellistic and Celyad Oncology announce transaction relating to cell therapy GMP manufacturing operations – 09/20/2022 at 07:00

Gosselies and Mont-Saint-Guibert, Belgium – Cellistic, the cell therapy development and manufacturing business of Ncardia and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on discovery and development of chimeric antigen receptor T-cell (CAR-T)-based cancer therapeutics, today announced the transaction whereby Cellistic will acquire Celyad Oncology’s cell therapy GMP manufacturing capacity, including the existing building and the related personnel (“The Operational Production Unit”).

Source link -86